Copy Number Alterations Independently Associated with Prognosis for Acute Leukemia

Share this content:

the Cancer Therapy Advisor take:

Copy number alterations (CNAs), specifically early B-cell factor 1 (EBF1), Ikaros family zinc finger 1 (IKZF1), and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletions, demonstrated an independent adverse prognosis for both adolescents and adults with B-precursor acute lymphoblastic leukemia (ALL), according to an article published online in the journal Cancer.

Participants in the study included 142 adolescents and adults diagnosed with de novo precursor B-cell ALL. The investigators analyzed the prognostic impact of CNAs of 12 genetic regions.

Results showed CDKN2A/B was the most frequent CNA (59 of 142; 42%) while IKZF1 was the second most frequent (49 of 142; 35%).

The IKZF1 deletions had a greater prevalence in Philadelphia chromosome (PH)-positive ALL and were linked to advanced age and high white blood cell (WBC) counts.

These IKZF1 deletions (HR, 1.869) and high WBC counts (HR, 1.005) were reported to be associated with disease recurrence.

Furthermore, EBF1 losses and advanced age were found to be associated with chemotherapy resistance in patients in the whole series (HR, 0.135 and 0.949, respectively) and the Ph-negative subgroup (HR, 0.118 and 0.946, respectively).

The authors determined advanced age and CDKN2A/B deletions influenced overall survival in both the whole series and the Ph-negative subgroup (HR, 1.038 vs. 1.044 and HR, 2.545 vs. 2.105, respectively).

FCR remains standard of care in very fit patients with chronic lymphocytic leukemia.
Copy number alterations demonstrated an independent adverse prognosis for B-precursor acute lymphoblastic leukemia.
How to Cite Ribera, J., Morgades, M., Zamora, L., Montesinos, P., Gómez-Seguí, I., Pratcorona, M., Sarrà, J., Guàrdia, R., Nomdedeu, J., Tormo, M., Martínez-Lopez, J., Hernández-Rivas, J.-M., González-Campos, J., Barba, P., Escoda, L., Genescà, E., Solé, F., Millá, F., Feliu, E., Ribera, J.-M.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs